成長ホルモン欠乏症の世界市場:疫学予測

◆英語タイトル:EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026
◆商品コード:GDHCER148-17
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年6月1日
◆ページ数:36
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:世界
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥439,450見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥878,900見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,318,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026
Summary

GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth (congenital), or it can be secondary due to brain trauma (acquired). Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. Patients who acquire GHD later in life present with more generalized symptoms, such as increased abdominal fat, decreased levels of energy, and decrease in muscle mass. In young children, certain kinds of cancer treatments, such as cranial radiation, can increase the chances of developing GHD. Other clinical procedures, such as brain surgery, can increase a patient’s chances of developing GHD. GHD may be hereditary, or it may be due to fetal malformation or genetic mutations. Acquired GHD can be caused by trauma to the head or brain and more commonly by a pituitary adenoma.

In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 109,551 cases in 2016 to 112,450 cases in 2026 at an Annual Growth Rate (AGR) of 0.26% in the 7MM. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of GHD in all markets except Germany and Japan. In 2016, the US made up about 48% of all diagnosed prevalent cases of GHD in the 7MM. In 2016, the 5EU made up approximately 40%, and Japan made up nearly 13% of all cases of GHD in the 7MM.

This 10-year epidemiological forecast of GHD is supported by data obtained from international GHD disease monitoring databases, country-specific government sources, as well as peer reviewed studies using market-relevant disease definitions across the 7MM. This forecast provides detailed segmentations within GHD for each market by the patient’s age, sex, and etiological classification (congenital and idiopathic in children, and idiopathic and acquired in adults), thus creating a comprehensive view of the epidemiology of GHD in the 7MM. GlobalData epidemiologists maintained consistent forecast methodology across all seven markets, thus allowing for an accurate and meaningful comparison of included parameters among them.

Scope

- The Growth Hormone Deficiency (GHD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of GHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD and adult onset GHD.
- The GHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The GHD EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global GHD market.
- Quantify patient populations in the global GHD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GHD therapeutics in each of the markets covered.
- Identify the percentage of GHD diagnosed prevalent cases by various clinical segmentations.

【レポートの目次】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 Related Reports 5
2.2 Upcoming Reports 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 8
3.3 Global and Historical Trends 9
3.3.1 GHD in children 10
3.3.2 GHD in adults 11
3.4 Forecast Methodology 11
3.4.1 Sources 13
3.4.2 Forecast Assumptions and Methods 16
3.5 Epidemiological Forecast for GHD (2016-2026) 22
3.5.1 Diagnosed Prevalent Cases of GHD 22
3.5.2 Age-Specific Diagnosed Prevalent Cases of GHD 23
3.5.3 Sex-Specific Diagnosed Prevalent Cases of GHD 24
3.5.4 Idiopathic and Organic GHD in Children 25
3.5.5 Congenital and Acquired GHD Out of Organic GHD in Children 26
3.5.6 Idiopathic and Acquired GHD in Adults 27
3.5.7 Onset Timing 28
3.6 Discussion 29
3.6.1 Epidemiological Forecast Insight 29
3.6.2 Limitations of Analysis 30
3.6.3 Strengths of the Analysis 30
4 Appendix 31
4.1 Bibliography 31
4.2 About the Authors 34
4.2.1 Epidemiologist 34
4.2.2 Reviewers 34
4.2.3 Global Director of Therapy Analysis and Epidemiology 35
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 35
4.3 About GlobalData 36
4.4 Contact Us 36
4.5 Disclaimer 36

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for GHD 8
Table 2: Diagnosed Prevalent Cases of GHD, Men and Women, All Ages, for 2016-2026. 22

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of GHD, Both Sexes, All Ages, 2016 and 2026 5
Figure 2: Age-Standardized Diagnosed Prevalence of GHD, Men and Women, All Ages, 2016 10
Figure 3: Case Flow Map of GHD 12
Figure 4: Sources Used and Not Used for the Diagnosed Prevalent Cases of GHD in Children 13
Figure 5: Sources Used and Not Used in the Forecast for Diagnosed Prevalent Cases of GHD in Adults 13
Figure 6 Sources Used and Not Used in the Forecast for Type of GHD in Children 14
Figure 7 Sources Used and Not Used in the Forecast for Type of GHD in Adults 15
Figure 8 Sources Used and Not Used in the Forecast for Onset Timing of GHD in Adults 16
Figure 9: Age-Specific Diagnosed Prevalent Cases of GHD, Men and Women, All Ages, 2016. 23
Figure 10: Sex-Specific Diagnosed Prevalent Cases, Men, Women, All Ages, 2016 24
Figure 11: Diagnosed Prevalent Cases of GHD in Children Segmented into Idiopathic and Organic GHD, Boys and Girls, Ages ≤18 years, 2016 25
Figure 12: Diagnosed Prevalent Cases of Congenital or Acquired GHD Out of Organic GHD, Boys and Girls, Ages ≤18 years, 2016 26
Figure 13: Idiopathic and Acquired GHD in Adults, Men and Women, Ages ≥19 Years, 2016. 27
Figure 14: Diagnosed Prevalent Cases by Onset Timing, Men and Women, Ages ≥19 Years, 2016. 28

【レポートのキーワード】

成長ホルモン欠乏症

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 成長ホルモン欠乏症の世界市場:疫学予測(EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆